Remo Guerrini

List of Publications by Year in Descending Order

257 papers	8,868 citations	49 h-index	79 g-index
261 ext. papers	9,430 ext. citations	5.2 avg, IF	5.33 L-index

#	Paper	IF	Citations
257	Pharmacology of Kappa Opioid Receptors: Novel Assays and Ligands.. *Frontiers in Pharmacology*, **2022**, 13, 873082	5.6	0
256	Fluorescent opioid receptor ligands as tools to study opioid receptor function. *Journal of Pharmacological and Toxicological Methods*, **2021**, 113, 107132	1.7	0
255	Structure-Activity Relationship Studies on Oxazolo[3,4-]pyrazine Derivatives Leading to the Discovery of a Novel Neuropeptide S Receptor Antagonist with Potent Activity. *Journal of Medicinal Chemistry*, **2021**, 64, 4089-4108	8.3	2
254	Folic Acid-Peptide Conjugates Combine Selective Cancer Cell Internalization with Thymidylate Synthase Dimer Interface Targeting. *Journal of Medicinal Chemistry*, **2021**, 64, 3204-3221	8.3	4
253	Novel Mixed NOP/Opioid Receptor Peptide Agonists. *Journal of Medicinal Chemistry*, **2021**, 64, 6656-6669	8.3	0
252	The N-terminal domain of Helicobacter pylori Hpn protein: The role of multiple histidine residues. *Journal of Inorganic Biochemistry*, **2021**, 214, 111304	4.2	1
251	Stress induces reinstatement of extinguished cocaine conditioned place preference by a sequential signaling via neuropeptide S, orexin, and endocannabinoid. *Addiction Biology*, **2021**, 26, e12971	4.6	2
250	Neuropeptide S-initiated sequential cascade mediated by OX, NK, mGlu and CB receptors: a pivotal role in stress-induced analgesia. *Journal of Biomedical Science*, **2020**, 27, 7	13.3	8
249	Cu(II) coordination to His-containing linear peptides and related branched ones: Equalities and diversities. *Journal of Inorganic Biochemistry*, **2020**, 205, 110980	4.2	2
248	Biased Agonism at Nociceptin/Orphanin FQ Receptors: A Structure Activity Study on N/OFQ(1-13)-NH. *Journal of Medicinal Chemistry*, **2020**, 63, 10782-10795	8.3	6
247	Bioinorganic chemistry of calcitermin - the picklock of its antimicrobial activity. *Dalton Transactions*, **2019**, 48, 13740-13752	4.3	8
246	Tetrabranched Hetero-Conjugated Peptides as Bifunctional Agonists of the NOP and Mu Opioid Receptors. *Bioconjugate Chemistry*, **2019**, 30, 2444-2451	6.3	3
245	Cyclic Peptides Acting as Allosteric Inhibitors of Human Thymidylate Synthase and Cancer Cell Growth. *Molecules*, **2019**, 24,	4.8	2
244	Nociceptin/orphanin FQ receptor agonists increase aggressiveness in the mouse resident-intruder test. *Behavioural Brain Research*, **2019**, 356, 120-126	3.4	6
243	Dopamine D and D receptors mediate neuropeptide S-induced antinociception in the mouse formalin test. *European Journal of Pharmacology*, **2019**, 859, 172557	5.3	6
242	Thermodynamic and spectroscopic study of Cu(ii) and Zn(ii) complexes with the (148-156) peptide fragment of C4YJH2, a putative metal transporter of Candida albicans. *Metallomics*, **2019**, 11, 1988-1998	4.5	5
241	NOP-Targeted Peptide Ligands. *Handbook of Experimental Pharmacology*, **2019**, 254, 17-36	3.2	4

240	Nociceptin/Orphanin FQ and Urinary Bladder. *Handbook of Experimental Pharmacology*, **2019**, 254, 347-365	3.2	7
239	Peptide welding technology - A simple strategy for generating innovative ligands for G protein coupled receptors. *Peptides*, **2018**, 99, 195-204	3.8	10
238	Glycation affects fibril formation of Aβ peptides. *Journal of Biological Chemistry*, **2018**, 293, 13100-13111	5.4	35
237	Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth. *Journal of Medicinal Chemistry*, **2018**, 61, 7374-7380	8.2	5
236	Design and Synthesis of TcN-Labeled Dextran-Mannose Derivatives for Sentinel Lymph Node Detection. *Pharmaceuticals*, **2018**, 11,	5.2	4
235	NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not R-ketamine. *Psychopharmacology*, **2018**, 235, 3093-3102	4.7	15
234	Zn(II) and Ni(II) complexes with poly-histidyl peptides derived from a snake venom. *Inorganica Chimica Acta*, **2018**, 472, 149-156	2.7	7
233	Central noradrenergic activity affects analgesic effect of Neuropeptide S. *Journal of Anesthesia*, **2018**, 32, 48-53	2.2	5
232	Pharmacological profile of the neuropeptide S receptor: Dynamic mass redistribution studies. *Pharmacology Research and Perspectives*, **2018**, 6, e00445	3.1	5
231	Disordered Peptides Looking for Their Native Environment: Structural Basis of CB1 Endocannabinoid Receptor Binding to Pepcans. *Frontiers in Molecular Biosciences*, **2018**, 5, 100	5.6	7
230	NOP receptor pharmacological profile - A dynamic mass redistribution study. *PLoS ONE*, **2018**, 13, e0203021	3.7	15
229	Urotensin-II peptidomimetic incorporating a non-reducible 1,5-triazole disulfide bond reveals a pseudo-irreversible covalent binding mechanism to the urotensin G-protein coupled receptor. *Organic and Biomolecular Chemistry*, **2017**, 15, 4704-4710	3.9	13
228	Effects of [Nphe, Arg, Lys] N/OFQ-NH (UFP-101), a potent NOP receptor antagonist, on molecular, cellular and behavioural alterations associated with chronic mild stress. *Journal of Psychopharmacology*, **2017**, 31, 691-703	4.6	20
227	A diastereoselective synthesis of Cebranopadol, a novel analgesic showing NOP/mu mixed agonism. *Scientific Reports*, **2017**, 7, 2416	4.9	6
226	Structure- and conformation-activity studies of nociceptin/orphanin FQ receptor dimeric ligands. *Scientific Reports*, **2017**, 7, 45817	4.9	4
225	Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt]N/OFQ(1-13). *European Journal of Pharmacology*, **2017**, 794, 115-126	5.3	18
224	In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403. *Pharmacology Research and Perspectives*, **2017**, 5, e00333	3.1	17
223	Neuropeptide S receptor ligands: a patent review (2005-2016). *Expert Opinion on Therapeutic Patents*, **2017**, 27, 347-362	6.8	12

222	DOES hemopressin bind metal ions in vivo?. *Dalton Transactions*, **2016**, 45, 18267-18280	4.3	4
221	In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations. *European Journal of Pharmacology*, **2016**, 793, 1-13	5.3	15
220	Intracellular quantitative detection of human thymidylate synthase engagement with an unconventional inhibitor using tetracysteine-diarsenical-probe technology. *Scientific Reports*, **2016**, 6, 27198	4.9	10
219	Nociceptin/orphanin FQ (N/OFQ) modulates immunopathology and airway hyperresponsiveness representing a novel target for the treatment of asthma. *British Journal of Pharmacology*, **2016**, 173, 1286-301	8.6	19
218	Antidepressant activity of nociceptin/orphanin FQ receptor antagonists in the mouse learned helplessness. *Psychopharmacology*, **2016**, 233, 2525-32	4.7	27
217	The unusual metal ion binding ability of histidyl tags and their mutated derivatives. *Dalton Transactions*, **2016**, 45, 5629-39	4.3	17
216	Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity. *Journal of Medicinal Chemistry*, **2016**, 59, 147-56	8.3	16
215	Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo). *PLoS ONE*, **2016**, 11, e0156897	3.7	21
214	Preferential interaction of the Alzheimer peptide A□(1-42) with Omega-3-containing lipid bilayers: structure and interaction studies. *FEBS Letters*, **2016**, 590, 582-91	3.8	10
213	Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist. *Pharmacology Research and Perspectives*, **2016**, 4, e00247	3.1	43
212	Neuropeptide S reduces mouse aggressiveness in the resident/intruder test through selective activation of the neuropeptide S receptor. *Neuropharmacology*, **2015**, 97, 1-6	5.5	14
211	Nociceptin/orphanin FQ and stress regulate synaptophysin expression in the rat fundic and colonic mucosa. *Tissue and Cell*, **2015**, 47, 147-51	2.7	2
210	Acute and subchronic antinociceptive effects of nociceptin/orphanin FQ receptor agonists infused by intrathecal route in rats. *European Journal of Pharmacology*, **2015**, 754, 73-81	5.3	17
209	Selective breeding for high anxiety introduces a synonymous SNP that increases neuropeptide S receptor activity. *Journal of Neuroscience*, **2015**, 35, 4599-613	6.6	43
208	The Importance of Ligand-Receptor Conformational Pairs in Stabilization: Spotlight on the N/OFQ G Protein-Coupled Receptor. *Structure*, **2015**, 23, 2291-2299	5.2	53
207	Intrathecal administration of nociceptin/orphanin FQ receptor agonists in rats: A strategy to relieve chemotherapy-induced neuropathic hypersensitivity. *European Journal of Pharmacology*, **2015**, 766, 155-62	5.3	15
206	Central adenosine A1 and A2A receptors mediate the antinociceptive effects of neuropeptide S in the mouse formalin test. *Life Sciences*, **2015**, 120, 8-12	6.8	16
205	In vitro and in vivo pharmacological characterization of a neuropeptide S tetrabranched derivative. *Pharmacology Research and Perspectives*, **2015**, 3, e00108	3.1	9

204	Physicochemical stability of cabazitaxel and docetaxel solutions. *European Journal of Hospital Pharmacy*, **2015**, 22, 150-155	1.6	3
203	Blockade of nociceptin/orphanin FQ receptor signaling reverses LPS-induced depressive-like behavior in mice. *Peptides*, **2015**, 72, 95-103	3.8	27
202	Structure activity studies of nociceptin/orphanin FQ(1-13)-NH2 derivatives modified in position 5. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 1515-20	3.4	4
201	Nociceptin/orphanin FQ induces simultaneously anxiolytic and amnesic effects in the mouse elevated T-maze task. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2015**, 388, 33-41	3.4	7
200	Neuropeptide S counteracts 6-OHDA-induced motor deficits in mice. *Behavioural Brain Research*, **2014**, 266, 29-36	3.4	16
199	Pharmacological characterization of tachykinin tetrabranched derivatives. *British Journal of Pharmacology*, **2014**, 171, 4125-37	8.6	12
198	Internalization and stability of a thymidylate synthase Peptide inhibitor in ovarian cancer cells. *Journal of Medicinal Chemistry*, **2014**, 57, 10551-6	8.3	9
197	Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth. *Journal of Medicinal Chemistry*, **2014**, 57, 1355-67	8.3	17
196	Mass spectrometric/bioinformatic identification of a protein subset that characterizes the cellular activity of anticancer peptides. *Journal of Proteome Research*, **2014**, 13, 5250-61	5.6	11
195	N-carbamidoyl-4-((3-ethyl-2,4,4-trimethylcyclohexyl)methyl)benzamide enhances staurosporine cytotoxic effects likely inhibiting the protective action of Magmas toward cell apoptosis. *Journal of Medicinal Chemistry*, **2014**, 57, 4606-14	8.3	3
194	Preparation and first biological evaluation of novel Re-188/Tc-99m peptide conjugates with substance-P. *Applied Radiation and Isotopes*, **2014**, 92, 25-31	1.7	20
193	Endogenous neuropeptide S tone influences sleep-wake rhythm in rats. *Neuroscience Letters*, **2014**, 581, 94-7	3.3	14
192	A novel and facile synthesis of tetra branched derivatives of nociceptin/orphanin FQ. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 3703-12	3.4	24
191	Hypothalamic neuropeptide S receptor blockade decreases discriminative cue-induced reinstatement of cocaine seeking in the rat. *Psychopharmacology*, **2013**, 226, 347-55	4.7	30
190	Ligands raise the constraint that limits constitutive activation in G protein-coupled opioid receptors. *Journal of Biological Chemistry*, **2013**, 288, 23964-78	5.4	18
189	Unexpected impact of the number of glutamine residues on metal complex stability. *Metallomics*, **2013**, 5, 214-21	4.5	27
188	Medicinal Chemistry, Pharmacology, and Biological Actions of Peptide Ligands Selective for the Nociceptin/Orphanin FQ Receptor. *ACS Symposium Series*, **2013**, 275-325	0.4	16
187	Neuropeptide S: a novel regulator of pain-related amygdala plasticity and behaviors. *Journal of Neurophysiology*, **2013**, 110, 1765-81	3.2	44

186	Nociceptin/orphanin FQ receptor activation decreases the airway hyperresponsiveness induced by allergen in sensitized mice. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2013**, 304, L657-64	5.8	19
185	Nociceptin/Orphanin FQ **2013**, 1577-1585		4
184	The nociceptin/orphanin FQ receptor antagonist UFP-101 reduces microvascular inflammation to lipopolysaccharide in vivo. *PLoS ONE*, **2013**, 8, e74943	3.7	11
183	Mixed tridentate □donor and monodentate □acceptor ligands as chelating systems for rhenium-188 and technetium-99m nitrido radiopharmaceuticals. *Current Radiopharmaceuticals*, **2013**, 6, 137-45	1.8	16
182	Anxiolytic- and panicolytic-like effects of Neuropeptide S in the mouse elevated T-maze. *European Journal of Neuroscience*, **2012**, 36, 3531-7	3.5	33
181	Thermodynamic and spectroscopic investigation on the role of Met residues in Cu(II) binding to the non-octarepeat site of the human prion protein. *Metallomics*, **2012**, 4, 794-806	4.5	17
180	Effects of neuropeptide S on seizures and oxidative damage induced by pentylenetetrazole in mice. *Pharmacology Biochemistry and Behavior*, **2012**, 103, 197-203	3.9	13
179	Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. *Nature*, **2012**, 485, 395-9	50.4	383
178	The coordination of NiII and Cu(II) ions to the polyhistidyl motif of Hpn protein: is it as strong as we think?. *Chemistry - A European Journal*, **2012**, 18, 11088-99	4.8	24
177	Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias. *Journal of Neuroscience*, **2012**, 32, 16106-19	6.6	34
176	Neuropeptide S inhibits stress-stimulated faecal output in the rat. *Pharmacological Research*, **2011**, 64, 471-7	10.2	10
175	Role of nociceptin/orphanin FQ receptors in the decrease of mucosal mast cells caused by acute stress in the rat colon. *Life Sciences*, **2011**, 89, 735-40	6.8	6
174	Effect of neuropeptide S receptor antagonists and partial agonists on palatable food consumption in the rat. *Peptides*, **2011**, 32, 44-50	3.8	20
173	UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor. *CNS Neuroscience and Therapeutics*, **2011**, 17, 178-98	6.8	33
172	Role of the ecto-nucleotidases in the cooperative effect of adenosine and neuropeptide-S on locomotor activity in mice. *Pharmacology Biochemistry and Behavior*, **2011**, 99, 726-30	3.9	12
171	Synthesis and separation of the enantiomers of the neuropeptide S receptor antagonist (9R/S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68). *Journal of Medicinal Chemistry*, **2011**, 54, 2738-44	8.3	19
170	Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, E542-9	11.5	66
169	In vitro activity of dermaseptin S1 derivatives against genital pathogens. *Apmis*, **2010**, 118, 674-80	3.4	12

168	Nociceptin modulates bronchoconstriction induced by sensory nerve activation in mouse lung. *American Journal of Respiratory Cell and Molecular Biology*, **2010**, 42, 250-4	5.7	28
167	Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68. *Peptides*, **2010**, 31, 915-25	3.8	47
166	Blockade of adenosine A2A receptor counteracts neuropeptide-S-induced hyperlocomotion in mice. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2010**, 381, 153-60	3.4	19
165	Anti-inflammatory and analgesic effects displayed by peptides derived from PKI55 protein, an endogenous protein kinase C inhibitor. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2010**, 382, 193-9	3.4	1
164	Long-lasting antinociceptive spinal effects in primates of the novel nociceptin/orphanin FQ receptor agonist UFP-112. *Pain*, **2010**, 148, 107-113	8	64
163	Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor. *Medicinal Research Reviews*, **2010**, 30, 751-77	14.4	75
162	In vitro and in vivo pharmacological characterization of the neuropeptide s receptor antagonist [D-Cys(tBu)5]neuropeptide S. *Journal of Pharmacology and Experimental Therapeutics*, **2009**, 328, 549-55	4.7	53
161	Nociceptin/orphanin FQ modulates motor behavior and primary motor cortex output through receptors located in substantia nigra reticulata. *Neuropsychopharmacology*, **2009**, 34, 341-55	8.7	22
160	Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24. *European Journal of Pharmacology*, **2009**, 614, 50-7	5.3	28
159	Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein G alpha qi5. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2009**, 379, 599-607	3.4	54
158	Desensitisation of native and recombinant human urotensin-II receptors. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2009**, 380, 451-7	3.4	5
157	Chronic treatment with the selective NOP receptor antagonist [Nphe 1, Arg 14, Lys 15]N/OFQ-NH 2 (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats. *Psychopharmacology*, **2009**, 207, 173-89	4.7	58
156	The paraventricular nucleus of the hypothalamus is a neuroanatomical substrate for the inhibition of palatable food intake by neuropeptide S. *European Journal of Neuroscience*, **2009**, 30, 1594-602	3.5	32
155	Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 5080-95	3.4	21
154	Synthesis and biological activity of human neuropeptide S analogues modified in position 5: identification of potent and pure neuropeptide S receptor antagonists. *Journal of Medicinal Chemistry*, **2009**, 52, 524-9	8.3	52
153	Further studies at neuropeptide s position 5: discovery of novel neuropeptide S receptor antagonists. *Journal of Medicinal Chemistry*, **2009**, 52, 4068-71	8.3	24
152	The hypothalamus-pituitary-adrenal axis does not influence the protective effects of nociceptin/orphanin FQ on the rat gastric mucosa. *Regulatory Peptides*, **2009**, 154, 32-8		3
151	Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor ligand ZP120. *Peptides*, **2009**, 30, 248-55	3.8	9

150	Structure-activity relationship study on Tyr9 of urotensin-II(4-11): identification of a partial agonist of the UT receptor. *Peptides*, **2009**, 30, 1130-6	3.8	8
149	The complex-formation behaviour of His residues in the fifth Cu2+ binding site of human prion protein: a close look. *New Journal of Chemistry*, **2009**, 33, 2300	3.6	22
148	Quantitative study of [(pF)Phe4,Arg14,Lys15]nociceptin/orphanin FQ-NH2 (UFP-102) at NOP receptors in rat periaqueductal gray slices. *European Journal of Pharmacology*, **2008**, 579, 110-5	5.3	5
147	Urotensin II evokes neurotransmitter release from rat cerebrocortical slices. *Neuroscience Letters*, **2008**, 440, 275-9	3.3	14
146	Structure-activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11). *Peptides*, **2008**, 29, 674-9	3.8	2
145	Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist. *Peptides*, **2008**, 29, 93-103	3.8	66
144	GABA(A) signalling is involved in N/OFQ anxiolytic-like effects but not in nocistatin anxiogenic-like action as evaluated in the mouse elevated plus maze. *Peptides*, **2008**, 29, 1404-12	3.8	14
143	Anxiolytic-like effect of neuropeptide S in the rat defensive burying. *Peptides*, **2008**, 29, 2286-91	3.8	81
142	CuII binding sites located at His-96 and His-111 of the human prion protein: thermodynamic and spectroscopic studies on model peptides. *Dalton Transactions*, **2008**, 5207-19	4.3	47
141	Synthesis and biological activity of human neuropeptide S analogues modified in position 2. *Journal of Medicinal Chemistry*, **2008**, 51, 655-8	8.3	25
140	The nociceptin/orphanin FQ-NOP receptor antagonist effects on an animal model of sepsis. *Intensive Care Medicine*, **2008**, 34, 2284-90	14.5	33
139	Binding of the novel radioligand [(3)H]UFP-101 to recombinant human and native rat nociceptin/orphanin FQ receptors. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2008**, 378, 553-61	3.4	16
138	Synthesis and antimicrobial activity of dermaseptin S1 analogues. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 8205-9	3.4	33
137	Structure-activity study at positions 3 and 4 of human neuropeptide S. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 8841-5	3.4	15
136	Study of synthetic peptides derived from the PKI55 protein, a protein kinase C modulator, in human neutrophils stimulated by the methyl ester derivative of the hydrophobic N-formyl tripeptide for-Met-Leu-Phe-OH. *FEBS Journal*, **2008**, 275, 449-57	5.7	1
135	Conformation-activity relationship of neuropeptide S and some structural mutants: helicity affects their interaction with the receptor. *Journal of Medicinal Chemistry*, **2007**, 50, 4501-8	8.3	20
134	Structural and dynamic characterization of copper(II) binding of the human prion protein outside the octarepeat region. *Chemistry - A European Journal*, **2007**, 13, 1991-2001	4.8	56
133	Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with Calpha,alpha-dialkylated amino acids. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 4434-43	3.4	48

132	Proinflammatory and vasodilator effects of nociceptin/orphanin FQ in the rat mesenteric microcirculation are mediated by histamine. *American Journal of Physiology - Heart and Circulatory Physiology*, **2007**, 293, H2977-85	5.2	32
131	UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ: behavioral and electrophysiological studies in mice. *Peptides*, **2007**, 28, 663-9	3.8	28
130	In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor. *Peptides*, **2007**, 28, 1240-51	3.8	65
129	Nociceptin/orphanin FQ prevents gastric damage induced by cold-restraint stress in the rat by acting in the periphery. *Peptides*, **2007**, 28, 1572-9	3.8	17
128	Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2006**, 373, 148-57	3.4	19
127	In vitro and in vivo pharmacological characterization of the nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-ol. *European Journal of Pharmacology*, **2006**, 539, 39-48	5.3	24
126	The alpha-to-beta conformational transition of Alzheimer's Abeta-(1-42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of beta conformation seeding. *ChemBioChem*, **2006**, 7, 257-67	3.8	314
125	Structure-activity studies on neuropeptide S: identification of the amino acid residues crucial for receptor activation. *Journal of Biological Chemistry*, **2006**, 281, 20809-20816	5.4	83
124	Daily intravesical instillation of 1 mg nociceptin/orphanin FQ for the control of neurogenic detrusor overactivity: a multicenter, placebo controlled, randomized exploratory study. *Journal of Urology*, **2006**, 176, 2098-102	2.5	30
123	Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: pharmacological and genetic evidences. *Pain*, **2006**, 124, 100-8	8	54
122	Chronic intracerebroventricular infusion of nociceptin/orphanin FQ increases food and ethanol intake in alcohol-preferring rats. *Peptides*, **2006**, 27, 2803-10	3.8	11
121	In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803). *British Journal of Pharmacology*, **2006**, 147, 92-100	8.6	29
120	Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 692-704	3.4	33
119	New approaches to high-throughput structure characterization of SH3 complexes: the example of Myosin-3 and Myosin-5 SH3 domains from S. cerevisiae. *Protein Science*, **2006**, 15, 795-807	6.3	12
118	Copper-ion interaction with the 106-113 domain of the prion protein: a solution-equilibria study on model peptides. *Dalton Transactions*, **2005**, 2876-85	4.3	23
117	N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands. *Journal of Medicinal Chemistry*, **2005**, 48, 1421-7	8.3	24
116	Conversion of the potent delta-opioid agonist H-Dmt-Tic-NH-CH(2)-bid into delta-opioid antagonists by N(1)-benzimidazole alkylation(1). *Journal of Medicinal Chemistry*, **2005**, 48, 8112-4	8.3	13
115	Nociceptin/orphanin FQ inhibits electrically induced contractions of the human bronchus via NOP receptor activation. *Peptides*, **2005**, 26, 1492-6	3.8	17

114	Nociceptin/orphanin FQ prevents ethanol-induced gastric lesions in the rat. *Regulatory Peptides*, **2005**, 124, 203-7		21
113	UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor. *CNS Neuroscience & Therapeutics*, **2005**, 11, 97-112		86
112	Modeling of overloaded gradient elution of nociceptin/orphanin FQ in reversed-phase liquid chromatography. *Journal of Chromatography A*, **2005**, 1079, 162-72	4.5	25
111	Activation of the nociceptin/orphanin FQ receptor reduces bronchoconstriction and microvascular leakage in a rabbit model of gastroesophageal reflux. *British Journal of Pharmacology*, **2005**, 144, 813-20	8.6	26
110	[Nphe1,Arg14,Lys15]N/OFQ-NH2 is a competitive antagonist of NOP receptors in the periaqueductal gray. *European Journal of Pharmacology*, **2005**, 515, 47-53	5.3	14
109	The interaction of highly helical structural mutants with the NOP receptor discloses the role of the address domain of nociceptin/orphanin FQ. *Chemistry - A European Journal*, **2005**, 11, 2061-70	4.8	16
108	Structure-activity relationship study on human urotensin II. *Journal of Peptide Science*, **2005**, 11, 85-90	2.1	32
107	Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. *Journal of Neuroscience*, **2005**, 25, 9591-601	6.6	105
106	Functional selectivity of nociceptin/orphanin FQ peptide receptor partial agonists on cardiovascular and renal function. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 314, 643-51	4.7	26
105	Peripheral mechanisms involved in gastric mucosal protection by intracerebroventricular and intraperitoneal nociceptin in rats. *Endocrinology*, **2005**, 146, 3861-7	4.8	21
104	[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 312, 1114-23	4.7	34
103	Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. *Journal of Neuroscience*, **2004**, 24, 6659-66	6.6	106
102	Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release. *Journal of Neurochemistry*, **2004**, 91, 1501-4	6	41
101	Solution structure of ZASP PDZ domain; implications for sarcomere ultrastructure and enigma family redundancy. *Structure*, **2004**, 12, 611-22	5.2	37
100	Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. *European Journal of Pharmacology*, **2004**, 498, 83-6	5.3	51
99	Functional coupling of the nociceptin/orphanin FQ receptor in dog brain membranes. *Brain Research*, **2004**, 1003, 18-25	3.7	7
98	Urotensin II stimulates plasma extravasation in mice via UT receptor activation. *Naunyn-Schmiedeberg's Archives of Pharmacology*, **2004**, 370, 347-52	3.4	17
97	Copper binding to the neurotoxic peptide PrP106-126: thermodynamic and structural studies. *ChemBioChem*, **2004**, 5, 349-59	3.8	58

96	Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on delta-opioid receptor selectivity and antagonism. *Journal of Medicinal Chemistry*, **2004**, 47, 4066-71	8.3	19
95	Solution structure of amyloid beta-peptide (25-35) in different media. *Journal of Medicinal Chemistry*, **2004**, 47, 4231-8	8.3	99
94	Interaction of calmodulin with the phosphofructokinase target sequence. *FEBS Letters*, **2004**, 577, 284-8	3.8	16
93	Gastrointestinal effects of intracerebroventricularly injected nociceptin/orphaninFQ in rats. *Peptides*, **2004**, 25, 1013-20	3.8	30
92	Characterization of nociceptin/orphanin FQ binding sites in dog brain membranes. *Anesthesia and Analgesia*, **2003**, 97, 741-747	3.9	4
91	Effects of nociceptin/orphanin FQ receptor ligands on blood pressure, heart rate, and plasma catecholamine concentrations in guinea pigs. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2003**, 367, 342-7	3.4	32
90	Synthesis and opioid activity of N,N-dimethyl-Dmt-Tic-NH-CH(R)-RQanalogues: acquisition of potent delta antagonism. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 5435-41	3.4	17
89	Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex. *British Journal of Pharmacology*, **2003**, 138, 91-8	8.6	50
88	Proteinase-activated receptor-1 (PAR-1) activation contracts the isolated human renal artery in vitro. *British Journal of Pharmacology*, **2003**, 139, 21-7	8.6	8
87	Nociceptin/Orphanin FQ(1-13)NH2 analogues modified in the Phe1-Gly2 peptide bond. *Bioorganic and Medicinal Chemistry Letters*, **2003**, 13, 365-8	2.9	13
86	Urodynamic effects of intravesical nociceptin/orphanin FQ in neurogenic detrusor overactivity: a randomized, placebo-controlled, double-blind study. *Urology*, **2003**, 61, 946-50	1.6	38
85	Effects of [(pF)Phe(4)]nociceptin/orphanin FQ-(1-13)NH(2) on GTPgamma(35)S binding and cAMP formation in Chinese hamster ovary cells expressing the human nociceptin/orphanin FQ receptor. *European Journal of Pharmacology*, **2002**, 443, 7-12	5.3	15
84	Effects of chronic nociceptin/orphanin FQ exposure on cAMP accumulation and receptor density in Chinese hamster ovary cells expressing human nociceptin/orphanin FQ receptors. *European Journal of Pharmacology*, **2002**, 449, 17-22	5.3	8
83	Pharmacological characterisation of [(pX)Phe4]nociceptin(1-13)amide analogues. 1. In vitro studies. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2002**, 365, 442-9	3.4	25
82	Pharmacological characterisation of [(pX)Phe4]nociceptin(1-13)NH2 analogues. 2. In vivo studies. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2002**, 365, 450-6	3.4	23
81	Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. *FEBS Journal*, **2002**, 269, 5642-8		470
80	Pharmacological profile of nociceptin/orphanin FQ receptors. *Clinical and Experimental Pharmacology and Physiology*, **2002**, 29, 223-8	3	53
79	Solution structure of nociceptin peptides. *Journal of Peptide Science*, **2002**, 8, 497-509	2.1	12

78	[Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. *British Journal of Pharmacology*, **2002**, 136, 303-11	8.6	148
77	Central injections of nocistatin or its C-terminal hexapeptide exert anxiogenic-like effect on behaviour of mice in the plus-maze test. *British Journal of Pharmacology*, **2002**, 136, 764-72	8.6	54
76	A new ligand for the urotensin II receptor. *British Journal of Pharmacology*, **2002**, 137, 311-4	8.6	48
75	[Arg(14),Lys(15)]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies. *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 300, 57-63	4.7	49
74	Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties. *Journal of Medicinal Chemistry*, **2002**, 45, 713-20	8.3	90
73	Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore. *Journal of Medicinal Chemistry*, **2002**, 45, 5556-63	8.3	75
72	The SH3 domain of nebulin binds selectively to type II peptides: theoretical prediction and experimental validation. *Journal of Molecular Biology*, **2002**, 316, 305-15	6.5	22
71	Crystal structures of dipeptides containing the Dmt-Tic pharmacophore. *Journal of Medicinal Chemistry*, **2002**, 45, 5506-13	8.3	13
70	Intrathecal [Nphe1]nociceptin(1-13)NH2 selectively reduces the spinal inhibitory effect of nociceptin. *Life Sciences*, **2002**, 70, 1151-7	6.8	11
69	[Nphe(1)]N/OFQ-(1-13)-NH(2) is a competitive and selective antagonist at nociceptin/orphanin FQ receptors mediating K(+) channel activation in rat periaqueductal gray slices. *Neuropharmacology*, **2002**, 42, 246-52	5.5	18
68	Pharmacological characterization of the nociceptin receptor which mediates reduction of alcohol drinking in rats. *Peptides*, **2002**, 23, 117-25	3.8	41
67	Generation of New Dint-Tic Opioid Antagonists: N-Alkylation **2002**, 603-604		
66	Synthesis and pharmacological activity of a new antagonist of the OP4 receptor **2002**, 227-228		
65	Endogenous nociceptin signaling and stress-induced analgesia. *NeuroReport*, **2001**, 12, 3009-13	1.7	33
64	Characterization of the locomotor activity-inhibiting effect of nociceptin/orphanin FQ in mice. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2001**, 363, 161-5	3.4	49
63	Effects of Ro 64-6198 in nociceptin/orphanin FQ-sensitive isolated tissues. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2001**, 363, 551-5	3.4	41
62	Effects of nociceptin and endomorphin 1 on the electrically stimulated human vas deferens. *British Journal of Clinical Pharmacology*, **2001**, 51, 355-8	3.8	11
61	Immunosensing by a Synthetic Ligand-Gated Ion Channel. *Angewandte Chemie - International Edition*, **2001**, 40, 1740-1743	16.4	57

60	Inhibition of human multidrug resistance P-glycoprotein 1 by analogues of a potent delta-opioid antagonist. *Brain Research*, **2001**, 902, 131-4	3.7	8
59	Copper complexes of glycyl-histidyl-lysine and two of its synthetic analogues: chemical behaviour and biological activity. *Biochimica Et Biophysica Acta - General Subjects*, **2001**, 1526, 199-210	4	37
58	Effects of nociceptinNH2 and [Nphe1]nociceptin(1-13)NH2 on rat brain noradrenaline release in vivo and in vitro. *Neuroscience Letters*, **2001**, 303, 173-6	3.3	22
57	Studies on the antinociceptive effect of [Nphe1]nociceptin(1-13)NH2 in mice. *Neuroscience Letters*, **2001**, 316, 25-8	3.3	28
56	URODYNAMIC AND CLINICAL EVIDENCE OF ACUTE INHIBITORY EFFECTS OF INTRAVESICAL NOCICEPTIN/ORPHANIN FQ ON DETRUSOR OVERACTIVITY IN HUMANS: A PILOT STUDY. *Journal of Urology*, **2001**, 166, 2237-2240	2.5	38
55	Structure-activity studies of the Phe(4) residue of nociceptin(1-13)-NH(2): identification of highly potent agonists of the nociceptin/orphanin FQ receptor. *Journal of Medicinal Chemistry*, **2001**, 44, 3956-64	8.3	37
54	Nociceptin/orphanin FQ exacerbates excitotoxic white-matter lesions in the murine neonatal brain. *Journal of Clinical Investigation*, **2001**, 107, 457-66	15.9	60
53	Computational Chemistry and Opioidmimetics: Receptor-Ligand Interactions of Dmt-Tic Peptides **2001**, 851-852		
52	Identification of a novel 45 kDa protein (JP-45) from rabbit sarcoplasmic-reticulum junctional-face membrane. *Biochemical Journal*, **2000**, 351, 537	3.8	8
51	Identification of a novel 45 kDa protein (JP-45) from rabbit sarcoplasmic-reticulum junctional-face membrane. *Biochemical Journal*, **2000**, 351, 537-543	3.8	26
50	The nociceptin/orphanin FQ receptor antagonist, [Nphe1]NC(1-13)NH2, potentiates morphine analgesia. *NeuroReport*, **2000**, 11, 2369-72	1.7	36
49	Characterization of N,N(Me)2-Dmt-Tic-OH, a delta selective opioid dipeptide antagonist. *NeuroReport*, **2000**, 11, 2083-6	1.7	2
48	Solution structure of nocistatin, a new peptide analgesic. *Biopolymers*, **2000**, 53, 257-64	2.2	7
47	Assessment of substitution in the second pharmacophore of Dmt-Tic analogues. *Bioorganic and Medicinal Chemistry Letters*, **2000**, 10, 2745-8	2.9	21
46	Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist. *British Journal of Pharmacology*, **2000**, 129, 1183-93	8.6	164
45	Pharmacology of nociceptin and its receptor: a novel therapeutic target. *British Journal of Pharmacology*, **2000**, 129, 1261-83	8.6	347
44	[Nphe(1)]nociceptin-(1-13)NH(2) selectively antagonizes nociceptin effects in the rabbit isolated ileum. *European Journal of Pharmacology*, **2000**, 397, 383-8	5.3	11
43	Inverse agonism by Dmt-Tic analogues and HS 378, a naltrindole analogue. *European Journal of Pharmacology*, **2000**, 406, R1-3	5.3	24

42	Further studies on nociceptin-related peptides: discovery of a new chemical template with antagonist activity on the nociceptin receptor. *Journal of Medicinal Chemistry*, **2000**, 43, 2805-13	8.3	66
41	Structure-activity relationships of nociceptin and related peptides: comparison with dynorphin A. *Peptides*, **2000**, 21, 923-33	3.8	37
40	Nociceptin/orphanin FQ receptor ligands. *Peptides*, **2000**, 21, 935-47	3.8	89
39	Studies of the cardiovascular effects of nociceptin and related peptides. *Peptides*, **2000**, 21, 985-93	3.8	22
38	Parallel bioassay of 39 tachykinins on 11 smooth muscle preparations. Structure and receptor selectivity/affinity relationship. *Peptides*, **2000**, 21, 1587-95	3.8	25
37	Opioid pseudopeptides containing heteroaromatic or heteroaliphatic nuclei. *Peptides*, **2000**, 21, 1663-71	3.8	22
36	Pain peptides. Solution structure of orphanin FQ2. *FEBS Letters*, **2000**, 473, 157-60	3.8	5
35	Supraspinal and spinal effects of [Phe1psi(CH2-NH)Gly2]-nociceptin(1-13)-NH2 on nociception in the rat. *Life Sciences*, **2000**, 66, 257-64	6.8	19
34	Cardiovascular effects of nociceptin in unanesthetized mice. *Hypertension*, **1999**, 33, 914-9	8.5	63
33	Comparison of the effects of [Phe1psi(CH2-NH)Gly2]nociceptin(1-13)NH2 in rat brain, rat vas deferens and CHO cells expressing recombinant human nociceptin receptors. *British Journal of Pharmacology*, **1999**, 127, 123-30	8.6	70
32	Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies. *Naunyn-Schmiedeberg's Archives of Pharmacology*, **1999**, 359, 160-7	3.4	92
31	[Nphe(1)]nociceptin-(1-13)-NH(2) antagonizes nociceptin effects in the mouse colon. *European Journal of Pharmacology*, **1999**, 385, R3-5	5.3	58
30	Structure-activity studies on nociceptin/orphanin FQ: from full agonist, to partial agonist, to pure antagonist. *Il Farmaco*, **1999**, 54, 810-25		30
29	Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus-associated malignancies. *European Journal of Immunology*, **1999**, 29, 2579-89	6.1	23
28	Further studies on the Dmt-Tic pharmacophore: hydrophobic substituents at the C-terminus endow delta antagonists to manifest mu agonism or mu antagonism. *Journal of Medicinal Chemistry*, **1999**, 42, 5010-9	8.3	68
27	Nociceptin receptor activation inhibits tachykinergic non adrenergic non cholinergic contraction of guinea pig isolated bronchus. *Life Sciences*, **1999**, 64, PL157-63	6.8	24
26	Nociceptin binding sites in frog (Rana esculenta) brain membranes. *Biochemical and Biophysical Research Communications*, **1999**, 260, 592-6	3.4	14
25	A new selective antagonist of the nociceptin receptor. *British Journal of Pharmacology*, **1998**, 123, 163-5	8.6	197

24	Rational design of dynorphin A analogues with delta-receptor selectivity and antagonism for delta- and kappa-receptors. *Bioorganic and Medicinal Chemistry*, **1998**, 6, 57-62	3.4	25
23	Design of δ opioid peptide antagonists for emerging drug applications. *Drug Discovery Today*, **1998**, 3, 284-294	8.8	40
22	High structural side chain specificity required at the second position of immunogenic peptides to obtain stable MHC/peptide complexes. *FEBS Letters*, **1998**, 421, 95-9	3.8	12
21	Ultraselective antagonists of the d-opioid receptor. *Expert Opinion on Therapeutic Targets*, **1998**, 2, 45-47		
20	Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist. *Journal of Medicinal Chemistry*, **1998**, 41, 3360-6	8.3	80
19	Opioid diketopiperazines: refinement of the delta opioid antagonist pharmacophore. *Biological Chemistry*, **1997**, 378, 107-14	4.5	28
18	Opioid diketopiperazines: synthesis and activity of a prototypic class of opioid antagonists. *Biological Chemistry*, **1997**, 378, 19-29	4.5	37
17	Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. *Journal of Medicinal Chemistry*, **1997**, 40, 1789-93	8.3	214
16	Helix-inducing alpha-aminoisobutyric acid in opioid mimetic deltorphin C analogues. *Journal of Medicinal Chemistry*, **1997**, 40, 2579-87	8.3	20
15	Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity. *Journal of Medicinal Chemistry*, **1997**, 40, 3100-8	8.3	81
14	Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides. *Journal of Medicinal Chemistry*, **1997**, 40, 2948-52	8.3	53
13	Design and solution structure of a partially rigid opioid antagonist lacking the basic center--models of antagonism. *FEBS Journal*, **1997**, 247, 66-73		21
12	Dmt-Tic-OH a highly selective and potent delta-opioid dipeptide receptor antagonist after systemic administration in the mouse. *Life Sciences*, **1996**, 59, PL93-8	6.8	23
11	Opioid receptor selectivity alteration by single residue replacement: synthesis and activity profile of [Dmt1]deltorphin B. *European Journal of Pharmacology*, **1996**, 302, 37-42	5.3	39
10	The mouse vas deferens: a pharmacological preparation sensitive to nociceptin. *European Journal of Pharmacology*, **1996**, 311, R3-5	5.3	111
9	Design and synthesis of 1-aminocycloalkane-1-carboxylic acid-substituted deltorphin analogues: unique delta and mu opioid activity in modified peptides. *Journal of Medicinal Chemistry*, **1996**, 39, 773-80	8.3	29
8	Polymorphonuclear neutrophils pulsed with synthetic peptides efficiently activate memory cytotoxic T lymphocytes. *Journal of Leukocyte Biology*, **1996**, 60, 207-13	6.5	26
7	Acid catalysis in the formation of dioxopiperazines from peptides containing tetrahydroisoquinoline-3-carboxylic acid at position 2. *International Journal of Peptide and Protein Research*, **1995**, 45, 567-73		20

6	Calmodulin binding sites of the skeletal, cardiac, and brain ryanodine receptor Ca2+ channels: modulation by the catalytic subunit of cAMP-dependent protein kinase?. *Biochemistry*, **1995**, 34, 5120-9	3.2	37
5	Opioidmimetic Antagonists: Prototypes for Designing a New Generation of Ultraselective Opioid Peptides. *Molecular Medicine*, **1995**, 1, 678-689	6.2	114
4	Conformationally constrained amino acids: A concise route to a methionine analogue. *Tetrahedron*, **1994**, 50, 12973-12978	2.4	5
3	Conversion of enkephalin and dermorphin into delta-selective opioid antagonists by single-residue substitution. *FEBS Journal*, **1994**, 224, 241-7		42
2	Synthesis and pharmacological activity of the N-terminal dermorphin tetrapeptide analogs with CH2-NH peptide bond isosteres. *International Journal of Peptide and Protein Research*, **1992**, 40, 437-44		7
1	Synthesis of spinacine and spinacine derivatives: crystal and molecular structures of N-hydroxymethyl spinacine and N-methyl spinaceamine. *Journal of Chemical Crystallography*, **1991**, 27, 507-513	0.5	8